PDCD1 and neoplasm: Another phase II study reported that 6 out of 15 patients resistant to PD-1 inhibitors experienced clinical benefits after receiving FMT from PD-1 inhibitor responders, including increased tumor microbial diversity, activation of CD8+ T cells, and a reduction in IL-8+ myeloid cells(NCT03341143) (97).